We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Global Viral Transport Medium Market Driven by Increasing Prevalence of Infectious Diseases

By LabMedica International staff writers
Posted on 25 Aug 2022

Viral transport medium (VTM) assumed importance globally when the new H1N1 influenza virus was identified, causing the world's first flu pandemic in more than 40 years. More...

Since then, it has been used majorly by hospitals, labs, and academic/research institutes for transporting viral samples across the research and clinical value chain. During the transport, the virus, if present, in the sample specimen should remain intact until the testing is completed. More recently, the sudden onset of the COVID-19 pandemic significantly boosted the demand for transport medium products and related kits. With the fast spread of the COVID-19 virus, many countries prioritized diagnostic testing for quick diagnosis of the virus, fuelling an exponential increase in the demand for VTM kits for sample collection from suspected COVID-19 patients. Other viral infections, such as influenza, herpes, varicella, respiratory syncytial virus, and viral infectious diseases, also demand quick diagnosis in which VTM kits play a vital role in the collection, preservation, and transportation of specimens. As a result, the global VTM market is expected to grow at a CAGR of 3.51% during 2022-2027, driven by the increasing prevalence of infectious diseases.

These are the latest findings of Research and Markets (Dublin, Ireland), the world’s largest market research store.

VTM kits are constantly in demand due to the increasing prevalence of infectious diseases. The rising prevalence of viral infectious diseases has fueled an increase in the use of VTM kits. Some of the viral infectious diseases are COVID-19, influenza virus, enterovirus D68, herpes, varicella, RSV, etc. For diagnosing these diseases, the collection of samples, preservation, and transportation is required, with VTM kits being the most prominently used solutions by practitioners.

The demand for viral transport increased exponentially during the COVID-19 pandemic. The rise in COVID-19 testing across the world led to an increase in the consumption rate of VTM test kits. Millions of COVID-19 tests were done daily from June 2020 to January 2022, which proved to be a major turning point for the VTM market. With academic/research institutes intensifying their experiments for developing vaccines and mass testing to stop the spread of COVID-19 globally, vendors also increased their manufacturing capacities and produced billions of VTM kits. The companies have been focusing on innovation and developing kits containing double-ended flocked swabs, vials, antibiotics, and other items that inhibit microbial contamination.

In addition, with the continuous increase in seasonal flu cases, manufacturers are also manufacturing viral transport for influenza tests, owing to influenza-related morbidity and mortality in many countries. Efforts to improve the diagnostic rate and accuracy of viral infectious diseases continue to drive the VTM market growth as this requires laboratory testing of clinical specimens to identify the virus, viral antigens, and antibodies. In addition, a rapid increase in the aging population, rise in the number of people undergoing various voluntary surgeries and other factors have also accelerated the requirement for various diagnostic tests that involve the use of VTM kits.

Geographically, North America accounts for the largest share of the global VTM market due to a high number of laboratory tests conducted during the pandemic, presence of biopharma companies, large number of laboratories, well-developed healthcare services, and research studies carried out in the region. Influenza viral infections continue to increase in the African, North America, and Asia Pacific regions, which will require quick diagnosis and the need for collection, preservation, and transportation of specimens, thereby driving the growth of the global VTM market.

 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.